Illumina and IBM team up to create a standardized gene sequencing process to help in cancer research.
DNA sequencing firm, Illumina Inc., creates a spin-off company, GRAIL, to develop of what might be the world’s first accessible and universal blood tests to detect early signs of cancer.
According to Illumina Inc, the $1,000 human genome sequencer has debuted. The genome sequencer dubbed HiSeq X has been designed to process 20,000 genomes a year that will cost $1,000 each.
Using the genetic sequencing firm Illumina, the test will provide information about 97 genes that influence the risk of cancer.
Researchers from the University of Sheffield School of Health and Related Research (ScHARR) are today making a series of recommendations for NHS mental health trusts to change the way they collect and use patient feedback to improve the quality of care for inpatients.